Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Arjun Oberoi, Sanofi-Aventis' vice president for business development Asia Pacific, mirrors his company's leadership ambitions in the Asian markets. Open to calculated risks and high on energy, Oberoi has played a leading role in clinching a few important deals for Sanofi such as last year's acquisition of China OTC play BMP Sunstone and its joint venture with Minsheng Pharmaceutical Group ('Sanofi Expands Consumer Health Reach With New Joint Venture In China,' PharmAsia News, Feb. 1, 2010).
Advertisement

Related Content

Sanofi Enters India’s Consumer Market With Universal Medicare Buy
Long Search Ends For Sanofi As It Buys Universal Medicare's Nutraceutical Brands In India
Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 1 of 2)
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
Sanofi Aventis Maps Out India R&D Strategy To Broaden Reach Into Untapped Markets
Sanofi Expands Consumer Health Reach With New Joint Venture In China
Sanofi Expands Consumer Health Reach With New Joint Venture In China
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
Advertisement
UsernamePublicRestriction

Register

SC078112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel